Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

17 Apr 2021

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.

2 Apr 2021

First cell-based gene therapy approved by the FDA for treating multiple myeloma

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

29 Mar 2021

New blood test makes it easier to follow the progression of multiple myeloma

A new method makes it much easier to follow the progression of multiple myeloma, a form of blood cancer.

26 Mar 2021

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can significantly reduce the risk of cancer--and especially obesity-related cancers--by as much as half in certain individuals, according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

26 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Underrepresentation in genomic databases may affect therapy selection for minority patients

Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.

19 Mar 2021

Novel cancer-fighting gene therapy enters phase I clinical trial

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells.

18 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.

2 Mar 2021

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.

15 Feb 2021

Immunomodulatory drugs improve the success rate of cancer therapies

Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide, have significantly improved the therapy of hematologic malignancies such as multiple myeloma.

15 Feb 2021

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma.

13 Feb 2021

Study provides new insights into the mechanism of bone marrow tissue

Imagine a day when clinicians treating people with blood diseases such as leukemia or multiple myeloma can send in requests for laboratories to custom-produce specific types of blood cells to replace those affected by the disease.

10 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

26 Jan 2021

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

20 Jan 2021

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Sharon Clark is able to get her life-sustaining cancer drug, Pomalyst — priced at more than $18,000 for a 28-day supply — only because of the generosity of patient assistance foundations.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Multiple Myeloma

Overview

Multiple Myeloma Diagnosis

Multiple Myeloma Pathophysiology

Multiple Myeloma Treatment

Feature Articles

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Researchers offer large-scale screening of potential broad-spectrum SARS-CoV-2 antivirals

First cell-based gene therapy approved by the FDA for treating multiple myeloma

New blood test makes it easier to follow the progression of multiple myeloma

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Underrepresentation in genomic databases may affect therapy selection for minority patients

Novel cancer-fighting gene therapy enters phase I clinical trial

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Immunomodulatory drugs improve the success rate of cancer therapies

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study provides new insights into the mechanism of bone marrow tissue

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Asthma Awareness: Fighting Asthma in 2021

World Asthma Day 2021: How could smart inhalers improve asthma care?

Fighting malaria in 2021: Where are we now and where are we going?

Multiple Myeloma

Overview

Feature Articles

Multiple Myeloma Epidemiology

Multiple Myeloma Symptoms

Management of Myeloma

Multiple Myeloma Imaging Strategies

Latest Multiple Myeloma News and Research

Newsletters you may be interested in